Home » Topics » Regulatory » EMA

EMA
RSS

EMA's CHMP recommends approval of Opdivo for two new indications

Feb. 29, 2016

EMA committee recommends E.U. approval of Alprolix to treat hemophilia B

Feb. 29, 2016

EMA CHMP issues positive opinion for ixekizumab for plaque psoriasis

Feb. 29, 2016

Gilead's Descovy receives positive CHMP opinion for HIV infection

Feb. 29, 2016

EMA grants orphan drug designation to TNT-009 for autoimmune hemolytic anemia

Feb. 26, 2016

European orphan drug designation for EYS-606 in refractory noninfectious uveitis

Feb. 26, 2016

EMA approves development strategy for Mologen's lefitolimod

Feb. 25, 2016

EMA creates Zika virus task force, HemispheRx announces its approach

Feb. 10, 2016

EMA confirms positive risk-benefit ratio of Xarelto for prevention of stroke in patients with AF

Feb. 8, 2016

EMA committee recommends approval of Coagadex to treat FX deficiency

Feb. 1, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.